Korea2026-04-249 min read

Lotte Chemical Closes Its Daesan Cracker and Pivots Toward Specialty Chemicals

Four consecutive years of operating losses. A ₩2.49 trillion net loss in FY2025. A dividend cut in half. A naphtha cracking facility consuming more cash than most Korean industrial companies generate in an entire year. By almost every conventional screen, Lotte Chemical Corporation (KRX: 011170) — one of South Korea's largest petrochemical producers, the company that converts crude oil derivatives into plastics, resins, and specialty materials — looks exactly like the kind of value trap a cautious international investor should avoid.

And yet on April 9, 2026, the stock jumped 8.41% in a single session to ₩99,300, and a week later Yuanta Securities published a 12-month price target of ₩165,000 — implying roughly 66% upside from that close. The reason for both the rally and the analyst's conviction is the same thing: Lotte Chemical is not a company declining into obsolescence. It is in the final stages of surgically removing its most destructive business line, and the three segments sitting directly underneath the loss-making headline — Advanced Materials, Fine Chemical, and an emerging Hydrogen and Battery Materials platform — are already profitable and growing. The market is pricing the losses it can see. It has not yet priced the company that emerges when those losses are gone.

Korea's First Government-Approved Petchem Consolidation

To understand why this moment is structural rather than cyclical, some context on what is happening across the Korean petrochemical sector is necessary.

A naphtha cracker (or NCC, naphtha cracking center) is the foundational facility of any integrated petrochemical operation: it takes naphtha — a liquid hydrocarbon refined from crude oil — and breaks it down under extreme heat into ethylene and propylene, the molecular building blocks used to manufacture virtually every plastic product. When the ethylene spread — the margin between naphtha feedstock costs and ethylene selling prices — is wide, crackers are cash machines. When it collapses, as it has throughout 2022–2025 under the weight of aggressive Chinese capacity additions, the cracker becomes a cash incinerator.

Korea built its petrochemical industry in three geographic clusters: Daesan, Yeosu, and Ulsan. All three are now under pressure from MOTIE, South Korea's Ministry of Trade, Industry and Energy, which brokered an agreement in August 2025 for Korean producers to reduce naphtha cracking capacity by 2.7 to 3.7 million tonnes per year — roughly a quarter of the national installed base. On February 25, 2026, MOTIE formally approved what it is calling the "Daesan No.1" restructuring project — the first government-sanctioned petrochemical industrial consolidation in Korean history. Lotte Chemical is its primary subject.

How the Restructuring Actually Works

The mechanics here are specific enough to be worth unpacking, because "restructuring" in a Korean industrial policy context involves capital instruments and binding timelines that don't have obvious Western equivalents.

  1. Permanent NCC shutdown. Lotte Chemical is permanently closing its Daesan naphtha cracker — 1.1 million tonnes per year of ethylene capacity, approximately 8% of Korea's total installed base. This is not a temporary curtailment or an extended maintenance pause. Equipment is being decommissioned. The capacity is being removed from the global supply base permanently.

  2. 50/50 joint venture with HD Hyundai Chemical. The downstream assets at Daesan — polyethylene and polypropylene conversion units, logistics, and utilities — are being folded into a new 50/50 joint venture with HD Hyundai Chemical, the petrochemical arm of the conglomerate behind Hyundai Heavy Industries. Lotte contributes ₩600 billion in fresh equity; HD Hyundai does the same. The JV is scheduled to launch in September 2026.

  3. The ₩2.1 trillion government support package. The most consequential element for JV viability: the government backstop includes up to ₩1 trillion in new financing for HD Hyundai Chemical, a ₩1 trillion conversion of existing bank loans into perpetual bonds (instruments with no maturity date that function as quasi-equity, removing near-term repayment pressure from the balance sheet), debt repayment deferrals through 2028, and waivers on acquisition and registration taxes that would otherwise be triggered by the asset transfer. Without this architecture, neither party could absorb the capital call.

  4. Workforce transition obligations. As reported by Seoul Economic Daily, Lotte is offering its 1,250 Daesan employees staggered severance bonuses of up to 500% of base salary through 2030, with HD Hyundai agreeing to re-absorb remaining staff in 2031. This is a multi-year cash commitment that will weigh on free cash flow even after the cracker's operating losses disappear — and it is one of the real execution risks for this thesis.

  5. Yeosu: the second phase. Lotte's Yeosu complex — its second NCC site — has submitted a separate restructuring plan to MOTIE. If approved, it triggers a further wave of capacity reduction. That approval is pending as of April 2026.

The Segments the Headlines Bury

Here is the data point that Lotte's headline earnings consistently obscure. The FY2025 operating loss of ₩943.6 billion — on revenue of ₩18.483 trillion, down 7.1% year-on-year — was not distributed across the company. It was concentrated almost entirely in one segment.

According to Lotte Chemical's official IR disclosures, the FY2025 segment breakdown was stark:

  • Basic Chemicals (the commodity naphtha cracker and polyolefin operations): operating loss of ₩847.6 billion at a –6.7% margin — the black hole of the portfolio
  • Advanced Materials (engineering plastics and specialty resins for automotive and electronics applications): operating profit of ₩208.5 billion at a +5.1% margin, up 16% year-on-year
  • Fine Chemical (specialty performance chemicals): operating profit of ₩74.4 billion at a +4.2% margin, up 48% year-on-year
  • Energy Materials (EV battery copper foil, via listed subsidiary Lotte Energy Materials): operating loss of ₩145.2 billion at a –21.4% margin — a separate and significant problem discussed below

Strip out Basic Chemicals and Energy Materials and the remaining portfolio generated ₩283 billion in operating profit in FY2025. Against a market capitalization of approximately ₩4.2 trillion (roughly $3.1 billion), that means the already-profitable segments are earning around 6.7% of the total market cap annually — in what industry participants are calling the worst petrochemical pricing environment in three decades.

Yuanta Securities analyst Hwang Kyuwon projects that once the restructuring completes, FY2027 revenue will fall to ₩13.1 trillion — Lotte is intentionally getting smaller — while operating profit reaches ₩591 billion. As Hwang noted in his April 2026 note: "The petrochemical industry restructuring will stabilize Lotte Chemical's financial position. Net debt is expected to decline, thereby strengthening its balance sheet." An operating profit of ₩591 billion on ₩13.1 trillion in revenue implies a 4.5% operating margin — modest by global specialty chemicals standards, but a complete reversal from the –5.1% margin that FY2025 produced.

At the company's April 16, 2026 CEO Investor Meeting in Seoul, CEO Youngjun Lee outlined the four growth pillars that define the post-restructuring portfolio: Advanced Materials, Specialty Chemicals, Battery Materials, and Hydrogen Energy. These are not aspirational slogans. At least two of them are already generating real profits.

The Advanced Materials Buildout

The most concrete near-term catalyst is Lotte Engineering Plastics' new 500,000-tonne-per-year compounding plant — the largest of its kind in Korea — targeting full operation in H2 2026. Compounding is the process of blending base resins with additives, fillers, and reinforcing agents to create engineered materials with specific mechanical, thermal, or electrical performance properties. The target application is Super Engineering Plastics, high-performance resins that replace metal in automotive structural components and high-heat electronics — products that carry substantially wider margins than commodity polyethylene or polypropylene.

The Green Hydrogen Position

LOTTE Fine Chemical completed what it claims is the world's first commercial-scale import of green ammonia — ammonia produced using renewable electricity rather than fossil fuel steam reforming — at Ulsan port in April 2026, sourced from China's Envision Group. The associated Lotte SK Eneroot hydrogen power plant at Ulsan is operational at 20 megawatts, with an 80-megawatt target by year-end. These numbers are small in the context of Lotte's total revenue base. But they signal a deliberate positioning in a value chain that Korean industrial policy is actively building incentives around.

What Could Break This Thesis

  • Chinese overcapacity proves structural rather than cyclical. The bull case assumes that removing 1.1 million tonnes of Korean ethylene capacity improves commodity spreads for Lotte's residual Basic Chemicals operations. If Chinese producers — who added approximately 15 million tonnes of new ethylene capacity between 2020 and 2025 — continue exporting at below-cost prices indefinitely, Asian spreads may not normalize on any timeline relevant to the investment horizon. Yuanta's ₩591 billion forecast requires both the restructuring to complete AND spreads to recover. Only one of those variables is within Lotte's control.

  • The EV copper foil bet continues to bleed. Lotte Energy Materials posted a –21.4% operating margin in FY2025, and the trajectory was deteriorating as the year ended. The company has committed over ₩1.4 trillion to EV battery copper foil capacity — the thin sheets of copper that form the current collector in lithium-ion battery anodes. Global EV demand has grown more slowly than the original investment thesis assumed, and battery manufacturer inventory destocking compressed volumes sharply through 2025. Further asset impairments on this position would hit net equity and represent a meaningful capital allocation failure at a moment when the company's balance sheet is already stretched, with total borrowings of ₩9.4 trillion at end-2025.

  • Daesan JV integration proves messier than projected. Managing a 1,250-person workforce transition across two corporate cultures — with staggered bonus payments through 2030 and a full personnel re-absorption commitment by HD Hyundai in 2031 — is a multi-year operational challenge. Disagreements between Lotte and HD Hyundai on JV strategy, or cost overruns on the transition commitments, could delay profitability for the combined entity well past the 2027 target.

  • Yeosu restructuring faces regulatory delay or union resistance. The Yeosu plan is submitted but not yet approved. If the second NCC reduction is deferred, the Basic Chemicals drag persists longer than Yuanta's model assumes, and the timeline for the post-restructuring margin profile shifts accordingly.

Conclusion

Lotte Chemical is not a cyclical recovery trade in the conventional sense — not the same business waiting for spreads to widen. It is a company in the process of becoming structurally different, and that transformation is now backed by government capital, binding JV agreements, and formal regulatory approvals that remove the optionality of reversing course.

At roughly ₩99,300 — well below consensus book value — the stock is priced as though the restructuring fails and the losses continue indefinitely. What it is not pricing is a portfolio in which the ₩847.6 billion Basic Chemicals drag has been removed, the Advanced Materials segment compounds at double-digit profit growth, the 500,000-tonne compounding plant is generating its first revenues, and green hydrogen earns its first meaningful contribution. Whether the execution delivers on that timeline involves genuine uncertainty — the copper foil business alone could absorb substantial additional capital before it earns its keep. But the optionality embedded in a post-restructuring Lotte Chemical is being offered, right now, at a price that assumes the surgery was never performed.